OTC Markets OTCPK - Delayed Quote USD

BioInvent International AB (publ) (BOVNF)

4.7000

0.0000

(0.00%)

At close: January 29 at 3:00:00 PM EST

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

ACCESS Newswire 20 days ago

BOVNF
0.00%
BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response ...

ACCESS Newswire 22 days ago

BOVNF
0.00%
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and ...

ACCESS Newswire 22 days ago

BOVNF
0.00%
BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in ...

ACCESS Newswire last month

BOVNF
0.00%
BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

LUND, SWEDEN and BOSTON, MA / ACCESSWIRE / December 3, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for ...

ACCESS Newswire last month

BOVNF
0.00%
Exploring High Growth Tech Stocks This November 2024

As global markets show resilience with major U.S. indexes approaching record highs and smaller-cap indexes outperforming, investor sentiment remains cautiously optimistic amid geopolitical tensions and economic uncertainties. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong fundamentals, innovative capabilities, and adaptability to evolving market conditions.

Simply Wall St. 2 months ago

BOVNF
0.00%
BioInvent International AB: Interim Report January-September 2024

LUND, SWEDEN / ACCESSWIRE / October 31, 2024 / BioInvent International (STO:BINV) "Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients. As part of our Q3 report, we are today pleased ...

ACCESS Newswire 2 months ago

BOVNF
0.00%
Invitation to Presentation of BioInvent’s Interim Report January - September 2024

LUND, SE / ACCESSWIRE / October 29, 2024 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2024 ...

ACCESS Newswire 3 months ago

BOVNF
0.00%
High Growth Tech Stocks In Sweden For October 2024

As the European Central Bank's recent rate cuts fuel optimism for further monetary easing, Sweden's tech sector remains a focal point for investors seeking high growth opportunities amidst a broader positive market sentiment. In this dynamic environment, identifying stocks with strong fundamentals and innovative capabilities can be key to capitalizing on potential growth in the Swedish tech landscape.

Simply Wall St. 3 months ago

BOVNF
0.00%
STRYF

BTRCF
High Growth Tech Stocks In Sweden To Watch Now

As global markets react to the Federal Reserve's recent rate cut, smaller-cap indices have shown promising performance despite remaining below previous peaks. This environment of monetary easing and economic optimism provides a fertile ground for high-growth tech stocks in Sweden, making it an opportune time to explore potential investments in this sector. Identifying strong candidates often involves looking at companies with robust innovation pipelines, solid financial health, and the...

Simply Wall St. 4 months ago

BOVNF
0.00%
STRYF

BTRCF
BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments

LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV) Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily ...

ACCESS Newswire 4 months ago

BOVNF
0.00%
BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place LUND, SE / ACCESSWIRE / September 12, 2024 /BioInvent ...

ACCESS Newswire 4 months ago

BOVNF
0.00%
BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part ...

ACCESS Newswire 4 months ago

BOVNF
0.00%
BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) ...

ACCESS Newswire 4 months ago

BOVNF
0.00%
BioInvent International AB: Interim Report January-June 2024

LUND, SWEDEN / ACCESSWIRE / August 29, 2024 / BioInvent International (STO:BINV) "The presentation of promising results from our two lead drug candidates at the ASCO Annual Meeting showcased their potential as first-in-class immunomodulatory agents ...

ACCESS Newswire 5 months ago

BOVNF
0.00%
Exploring 3 High Growth Tech Stocks in Sweden

As Sweden's Riksbank reduces borrowing costs, the Swedish tech sector is poised for potential growth amidst favorable economic conditions. In this article, we will explore three high-growth tech stocks in Sweden that stand out due to their innovative capabilities and strong market positioning.

Simply Wall St. 5 months ago

STRYF

BOVNF
0.00%
BTRCF
BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Allowed US patent application for anti-TNFR2 antibody BI-1910 covers composition-of-matter protection and the use of antibody to treat cancer Patent will further strengthen IP protection of BioInvent's innovative portfolio of clinical assets BI-1910 ...

ACCESS Newswire 5 months ago

BOVNF
0.00%
BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO

LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 ...

ACCESS Newswire 6 months ago

BOVNF
0.00%
BioInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA (Pembrolizumab) and Ipilimumab

LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with ...

ACCESS Newswire 6 months ago

BOVNF
0.00%
BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 at PAGE 2024

Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster ...

ACCESS Newswire 7 months ago

BOVNF
0.00%

Performance Overview

Return	BOVNF	OMX Stockholm 30 Index
YTD	0.00%	+7.22%
1-Year	0.00%	+12.43%
3-Year	+57.72%	+17.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioInvent International AB (publ) (BOVNF)

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

Exploring High Growth Tech Stocks This November 2024

BioInvent International AB: Interim Report January-September 2024

Invitation to Presentation of BioInvent’s Interim Report January - September 2024

High Growth Tech Stocks In Sweden For October 2024

High Growth Tech Stocks In Sweden To Watch Now

BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments

BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

BioInvent International AB: Interim Report January-June 2024

Exploring 3 High Growth Tech Stocks in Sweden

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO

BioInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA (Pembrolizumab) and Ipilimumab

BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 at PAGE 2024

Performance Overview